Critical element that improves vascular function in postmenopausal women found

Researchers studying why arteries stiffen in postmenopausal women have found a specific chemical cofactor that dramatically improves vascular function.

Kerrie Moreau, Ph.D., Associate Professor of Medicine at the University of Colorado School of Medicine, discovered that BH4 or tetrahydrobiopterin plays a key role in arterial health of women. BH4 is a critical cofactor of the enzyme endothelial nitric oxide synthase or eNOS. The two combine to create nitric oxide which is highly beneficial to arterial health.

"Nitric oxide causes arteries to dilate, without it they are more constricted which can lead to arterial stiffening. That stiffening can cause , thickening of the and increase the risk for stroke, heart disease and dementia" said Moreau, who works in the Division of Geriatrics at CU School of Medicine. "If there is not enough BH4, the eNOS enzymatic function does not work as well and less nitric oxide is produced. That leads to an increase in free radical formation or oxidative stress. Increased oxidative stress can decrease the amount of nitric oxide and BH4, creating a ."

The study will be published in the – Heart and Circulatory Physiology.

Moreau, the lead researcher in the study, gave BH4 to estrogen-deficient, postmenopausal women and assessed them three hours later. She found that dilation of the arteries increased while stiffness decreased. When premenopausal women were given BH4, nothing happened.

Researchers also took two groups of and gave one group a placebo and the other estrogen patches. They examined the results 48 hours later and discovered those who took estrogen experienced similar effects to those given BH4 while the women who received placebos experienced no changes. When the women who were taking estrogen were also given BH4 there was no further benefit.

"That suggests estrogen may benefit by maintaining BH4 levels," Moreau said. "Having adequate BH4 levels would result in increased and decreased free radicals, promoting vasodilatation and reducing arterial stiffness."

It has been long known that menopause has significant impacts on women's health.

"Menopause is like an accelerated aging process," Moreau said."When women hit menopause you see this dramatic decline in arterial health." Moreau's discovery of the key role BH4 plays in this process sheds more light on the decline in arterial health and why it may not be inevitable.

"As we identify the causes of the vascular health decline we can next intervene with appropriate therapeutic strategies including exercise, diet and/or hormone therapy," she said. "Heart disease is the number one killer of men and women but it is underappreciated in women who need a better understanding of cardiovascular health."

Provided by University of Colorado Denver

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New therapy could preserve vessel function after heart attack

Sep 10, 2007

Scientists have identified the process that causes blood vessels to constrict during and after a heart attack. They've also demonstrated that delivering a vital molecule that is depleted during this process directly to those ...

Compound Shows Promise Against Intractable Heart Failure

Feb 11, 2010

(PhysOrg.com) -- A chemical compound found normally in the blood has shown promise in treating and preventing an intractable form of heart failure in a mouse model of the disease, report researchers at the University of Illinois ...

Drug therapy for PKU reverses heart damage

May 13, 2008

A pricy drug used to treat a rare but well-known genetic disorder may hold wider promise as a treatment for millions of Americans with potentially lethal enlarged hearts, due mainly to high blood pressure, a study from Johns ...

Oregon study raises questions on synthetic progestins

Mar 10, 2008

The widely used synthetic progestin medroxyprogesterone acetate (MPA) decreased endothelial function in premenopausal women in a study done at the University of Oregon. The finding, researchers said, raises concerns about ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.